Organ-izing the Future: Navigating Innovation and Ethical Challenges in Transplantation

Joshua Azariah[1]

[1]Department of Integrated Biomedical Engineering & Health Sciences, Faculty of Engineering, McMaster University, Hamilton, ON, Canada

Date Published: August 5, 2025
DOI: https://doi.org/10.18192/UOJM.V15iS2.7529

Organ transplantation represents a major medical advancement that has been consistently improved through ongoing developments. Its significance is emphasized by recent research demonstrating organ transplantation's substantial impact on improving quality of life (QoL) [1]. The Canadian Institute for Health Information (CIHI) reports that approximately 3,428 organ transplants were conducted in Canada in 2023 [2]. Advancements in biotechnology have been shown to have a profound impact on solid organ transplantation. For example, the use of spatial transcriptomics in organ transplantation shows promising results, providing hope to refine transplant rejection phenotypes and scoring [3]. However, advancements present significant ethical challenges, particularly pertaining to 3D-printed organs and xenotransplantation. These issues must be thoughtfully addressed to ensure that organ transplantation practices remain ethical and responsible.

Advancements in biological tissue engineering have led to several breakthroughs in building various vascularized tissues for organs, including the heart, liver, lung and kidney [4]. Recently, tissue engineering technologies for the creation of vascular networks have also begun to include microfluidics, organ-on-chip systems, and 3D printing [4]. Building an artificial organ using 3D printing involves constructing a three-dimensional pre-designed microstructure through the integration of multiple 2D patterns generated by computer-aided technology [5]. This procedure leads to a scaffold consisting of precise deposition of biomaterials [4]. In essence, 3D printing is an excellent alternative to traditional organ transplants with a donor and recipient, however, clinical trials are still needed to establish their safety and efficacy. Another transplantation approach is xenotransplantation, which entails transferring animal organs into humans [6]. The main challenges associated with xenotransplantation include the risk of organ rejection due to the recipient's immune response and the potential for cross-species transmission of pathogens [6]. However, several advancements have been made over the years to enhance xenograft survival. For example, attempts have been made to alleviate the host response by genetically modifying the donor animals [6]. Molecular mechanisms underlying host immune rejection alongside strategies to overcome them have also been identified. Nevertheless, significant health and ethical concerns regarding xenotransplantation persist.

As previously noted, ethical dilemmas related to organ transplantation must be addressed. One notable ethical issue is the use of xenogeneic cells in 3D-printed organs. The primary concern pertains to potential psychological and sociological problems that may arise [7]. These may include psychosocial problems associated with the recipient's identity resulting from xenotransplantation or cognitive dissonance due to religious beliefs involving a disagreement with the use of cells from animals [7]. An alternative to avoid these ethical concerns involves the use of induced pluripotent stem cells (iPSCs), which can be manipulated to differentiate into a variety of different adult body cell types to be deposited onto a 3D-printed scaffold [7]. However, the application of iPSCs requires genetic screening of the lines of stem cells for their appropriateness for medical use [7]. Other concerns include the protection of human rights, such as the handling and processing of organ models in 3D, representing personalized data of humans. Some of the key questions like "Who will hold legal rights to the model?" [7] and "Can the model be used without the consent of the patient?" [7]—bring out the need for the protection of privacy of information about patients.

Following the several ethical dilemmas revolving around organ transplantation, it is vital to recognize the need for robust ethical and regulatory frameworks to guide the development and use of these technologies. The importance of establishing ethical frameworks extends

far beyond clinical feasibility. Government policymakers endeavouring to improve the accessibility and equity of health care in general strive that such technological developments do not exacerbate any existing disparities or create new ones [8]. To ensure this, they work to implement equitable allocation processes, promote transparency of decision-making processes and protect patient rights. Policymakers very much desire a fine balance between innovation and ethical concerns with the idea of making progress while being fair and protecting the interest of patients [8]. Further, there must be constant monitoring and revision in policy for emerging challenges to address so that such advancement finally benefits diverse populations without affecting their ethical standards.

In conclusion, organ transplantation has evolved alongside advancements in tissue engineering and has shown promising results for future transplantation. It is in this respect that organ transplantation calls for a feasible integration of ethical frameworks with concerns for patient safety and policymaking. The barriers to organ donation factors, as found across the world, call for urgent attention to constructing and sustaining trust between people and their health systems. Guarantees for the applicability of ethical practices under transparent policies are important in building confidence and having an overall impact on effectiveness and equitability in transplantation processes.

REFERENCES

1. de Boer SE, Knobbe TimJ, Kremer D, van Munster BC, Nieuwenhuijs-Moeke GJ, Pol RA, et al. Kidney Transplantation Improves Health-Related Quality of Life in Older Recipients. Transplant International. 2024 Apr 15;37.
2. Summary statistics on organ transplants, wait-lists and donors | CIHI [Internet]. www.cihi.ca. 2023. Available from: https://www.cihi.ca/en/summary-statistics-on-organ-transplants- wait-lists-and-donors
3. Li JSY, Raghubar AM, Matigian NA, Ng MSY, Rogers NM, Mallett AJ. The Utility of Spatial Transcriptomics for Solid Organ Transplantation. Transplantation. 2023 Jul 20;107(7):1463–71.
4. Zheng K, Chai M, Luo B, Cheng K, Wang Z, Li N, et al. Recent progress of 3D printed vascularized tissues and organs. Smart Mater Med. 2024 Jun;5(2):183–95.
5. Mota C, Camarero-Espinosa S, Baker MB, Wieringa P, Moroni L. Bioprinting: From Tissue and Organ Development to in Vitro Models. Chem Rev. 2020 Oct 14;120(19):10547–607.
6. Ali A, Kemter E, Wolf E. Advances in Organ and Tissue Xenotransplantation. Annu Rev Anim Biosci. 2024 Feb 15;12(1):369–90.
7. Kirillova A, Bushev S, Abubakirov A, Sukikh G. Bioethical and Legal Issues in 3D Bioprinting. Int J Bioprint. 2020;6(3):272.
8. Then SN, Martin DE, McGee A, Gardiner D, El Moslemani N. Decision-making About Premortem Interventions for Donation: Navigating Legal and Ethical Complexities. Transplantation. 2023 Aug 18;107(8):1655–63.